AGP H1 2026 Results: Margin Resilience, Weaker Revenue

Company Name: AGP Ltd | Ticker: AGP | Reporting period: six months ended June 30, 2026 | Reporting basis: consolidated

AGP Ltd (AGP) reported a softer first half of 2026 on a consolidated basis. The operating picture was weaker than the nearly flat EPS suggests: revenue contracted, operating profit fell faster than gross profit, and the second quarter showed a sharper top-line slowdown. Better gross margin, lower finance cost and a much lighter tax charge absorbed part of that pressure, leaving earnings attributable to ordinary shareholders broadly stable.

Results at a glance

H1 revenue: PKR 11.53 billion, down 9.4% year on year from PKR 12.72 billion.
H1 gross profit: PKR 6.85 billion, down 7.2%; gross margin improved to about 59.4% from 58.0%.
H1 operating profit, derived from reported operating line items: about PKR 2.80 billion, down roughly 17.7%, with operating margin easing to about 24.3% from 26.8%.
H1 finance cost: PKR 660.3 million, down 11.6%.
H1 profit before tax: PKR 2.11 billion, down 20.5% after a new levy charge of about PKR 29.6 million.
H1 consolidated profit for the period: PKR 1.55 billion, down 8.2%; basic and diluted EPS was PKR 5.21 versus PKR 5.25.
Q2 revenue: PKR 4.68 billion, down 15.9% year on year; Q2 attributable net income was about PKR 601 million and EPS PKR 2.15.
Interim cash dividend: PKR 2.00 per share.

Verdict

The half-year result is mixed rather than simply weak. AGP protected gross margin unusually well despite lower sales, and finance-cost relief helped below the operating line. But the more important signal is that operating profit fell materially faster than revenue because marketing and administrative expenses did not decline with the top line. A lower tax burden then cushioned the final EPS outcome. In other words, the reported EPS stability overstates the resilience of the core operating trend.

Q2 makes that distinction clearer. Sales fell almost 16% from the comparable quarter, while attributable earnings declined only modestly. That gap is encouraging only if revenue stabilizes and cost discipline converts the margin gains into operating growth. If the top-line contraction persists, tax and financing relief cannot indefinitely substitute for stronger product volumes, pricing, mix and commercialization.

AlphaGen model context

The following are AlphaGen model outputs and are not company-reported financial figures.

Alpha QoQ Score: 5.09
TTM Performance Score: 58.79
3Y Business Perf Score: 85.56
Sector Leadership Score: 26.1075

What improved

Gross-margin defense was the clearest operating positive. Cost of sales fell about 12.4%, faster than the 9.4% decline in revenue, lifting H1 gross margin by roughly 1.4 percentage points. This suggests a better product mix, procurement outcome, pricing discipline or combination of these factors, although the result announcement does not isolate the exact contribution of each driver.
Finance cost moved in the right direction. It declined by about PKR 86.6 million, or 11.6%, helping offset some of the pressure from lower operating profit. For a pharmaceutical group that has used debt to support acquisitions and working capital, continued debt-cost normalization would improve the quality of future earnings recovery.
The effective tax burden was materially lighter. Current and deferred tax together were about PKR 559.5 million versus PKR 966.7 million a year earlier. This was a major reason the decline in profit after tax was much smaller than the decline in profit before tax.
The group continued to expand its commercial portfolio. During 2026 AGP disclosed an arrangement to market Xanax in Pakistan through an associated-company structure, adding another recognizable prescription brand to its commercialization platform.

What weakened / needs attention

Revenue momentum weakened. H1 sales fell 9.4%, and Q2 sales fell 15.9% year on year, indicating that the slowdown intensified during the second quarter rather than being confined to the opening months of the year.
Operating leverage worked in the wrong direction. Marketing and selling expense rose about 1.8% and administrative expense about 2.9% even as revenue declined. That pushed the derived operating margin down by roughly 2.5 percentage points year on year.
Pre-tax profit fell about 20.5%. That is a cleaner indicator of the operating and financing trajectory than the almost unchanged EPS because it is not cushioned by the unusually favorable year-on-year tax comparison.
The difference between consolidated profit and EPS matters. Total group profit for the period was down about 8%, while EPS declined less than 1%, reflecting the allocation of earnings between AGP shareholders and non-controlling interests. Investors should therefore track both consolidated profit and profit attributable to owners rather than relying only on EPS.
Corporate restructuring adds execution complexity. Shareholders approved a Scheme of Arrangement involving AGP and associated entities in June 2026, subject to the required legal process. The structure may simplify or realign group operations, but it should be judged on eventual economics rather than assumed synergies.

Revenue and gross profit: lower sales, better unit economics

AGP generated PKR 11.53 billion of consolidated revenue in H1 2026 compared with PKR 12.72 billion a year earlier. The 9.4% decline is the central weakness in the result. The second quarter was softer still, with revenue of PKR 4.68 billion versus PKR 5.56 billion in Q2 2025. That puts the burden on management to restore commercial momentum in the second half.

The gross-profit line was more resilient. Gross profit declined 7.2% to PKR 6.85 billion, less than the fall in sales. Gross margin increased to about 59.4% from 58.0%. For a branded pharmaceutical business, this can be economically meaningful because gross margin reflects product mix, pricing, manufacturing efficiency and imported-input economics before the heavy selling infrastructure is absorbed.

The key question is whether the margin improvement can persist when revenue returns to growth. A richer product mix and better pricing can support structurally higher gross margin; temporary procurement or inventory effects cannot. Until the full interim report gives more segment and cost detail, the safer interpretation is that margin defense was real, but its durability still needs confirmation.

Operating expenses: commercial intensity diluted the margin gain

AGP did not convert the gross-margin improvement into a comparable operating-profit outcome. Marketing and selling expenses increased to PKR 3.49 billion from PKR 3.43 billion, while administrative expenses rose to PKR 444.9 million from PKR 432.3 million. Other operating income also declined slightly.

Using the reported operating line items, operating profit was about PKR 2.80 billion compared with roughly PKR 3.41 billion a year earlier, a decline near 17.7%. Operating margin consequently fell to about 24.3% from 26.8%. This is the most important operational tension in the half-year result: the business protected product-level margin, but its commercial and administrative cost base did not flex with lower revenue.

That does not automatically mean the spending is inefficient. Pharmaceutical companies often invest ahead of revenue through sales-force expansion, new product launches and brand support. But the burden of proof shifts to subsequent quarters: if higher commercial spending supports renewed growth, the current expense pressure may be productive; if revenue remains weak, it becomes a structural margin concern.

Below the operating line: finance relief helped, tax relief helped more

Finance cost declined to PKR 660.3 million from PKR 746.8 million. That is supportive, especially after Pakistan's broader interest-rate cycle eased from earlier peaks. The benefit, however, was not enough to offset lower operating profit. Profit before income tax and levies fell about 19.4%, and after the new levy line profit before tax was PKR 2.11 billion, down about 20.5%.

The decisive cushion came from tax. Net tax expense fell to about PKR 559.5 million from PKR 966.7 million, a reduction of roughly 42%. Consolidated profit for the period therefore declined only 8.2% to PKR 1.55 billion. Earnings attributable to ordinary shareholders were more resilient still, which is why EPS moved only from PKR 5.25 to PKR 5.21.

This distinction matters for forecasting. The cleaner route to stronger future earnings is a recovery in revenue and operating profit, supplemented by lower finance cost. A favorable tax comparison can make one period look better, but it is less reliable as the foundation for a multi-quarter earnings trend.

Q2 versus the prior-year quarter

The second quarter produced PKR 4.68 billion of sales compared with PKR 5.56 billion a year earlier, a decline of about 15.9%. Attributable net income was approximately PKR 601 million versus PKR 617 million, while EPS was PKR 2.15 against PKR 2.20.

The near-flat bottom line should not obscure the revenue contraction. The quarter suggests that gross-margin and below-the-line offsets were doing substantial work. The next result should therefore be read first through sales growth, gross margin and operating expenses, and only then through EPS.

Corporate actions and operating developments

AGP entered 2026 with an active capital-allocation and portfolio agenda. The company conducted a share buy-back program during the year, while its shareholders later approved a corporate reorganization scheme involving associated entities. These actions can alter ownership, group structure and capital deployment, but neither should be treated as a substitute for operating growth.

On the commercial side, AGP disclosed an arrangement to undertake marketing services for Xanax in Pakistan through an associated company, with commercialization expected after completion of formalities. This is relevant because AGP's model combines manufacturing with brand commercialization and licensed or acquired product portfolios. The economic impact should be judged through actual sales contribution and marketing productivity rather than the brand announcement alone.

After the reporting period, AGP also clarified that a government alert concerning a counterfeit Azomax batch did not relate to genuine AGP-manufactured product. The immediate disclosure reduces the risk of confusing the counterfeit issue with AGP's legitimate product quality, although brand perception and regulatory communication remain worth monitoring.

How to read the next results

Revenue growth: the first priority is whether the Q2 contraction reverses. A return to positive growth would make the H1 gross-margin improvement much more valuable.
Gross margin: watch whether the roughly 59% H1 level is sustained and whether management attributes the improvement to durable mix/pricing or temporary input effects.
Marketing and selling expense: this needs to generate visible revenue productivity. Expense growth without top-line growth would keep operating leverage negative.
Operating margin: this is the cleanest test of whether gross-margin gains are being converted into core profitability.
Finance cost: continued easing would support earnings, but the benefit should be assessed alongside borrowing and working-capital needs.
Tax rate and levies: H1 benefited from a much lighter tax charge, so future comparisons should separate operating improvement from tax normalization.
New-product contribution: track whether additions such as Xanax and other portfolio initiatives become measurable revenue rather than remaining qualitative growth narratives.
Group restructuring: monitor court and regulatory completion, the final entity structure, accounting effects and any disclosed operating or capital-allocation synergies.

What to monitor next

Whether Q3 consolidated revenue returns to growth after the 15.9% Q2 decline.
Whether gross margin remains above the prior-year level while commercial spending is brought back into line with sales growth.
Whether profit before tax improves without relying on another unusually favorable tax comparison.
The scale and profitability of newly commercialized brands and the contribution from associated-company arrangements.
Any material accounting, ownership or operational effects from the approved Scheme of Arrangement.
Dividend coverage and the balance between cash distributions, buy-backs, debt reduction and investment in new products.

Bottom line

AGP's H1 2026 result shows a business that still has meaningful gross-margin resilience but needs a stronger top line. The 9.4% H1 revenue decline and 17.7% derived operating-profit decline are more important than the nearly flat EPS. Lower finance cost and tax relief did useful work, while the product pipeline and group restructuring provide potential future catalysts. The next quarter should be judged primarily on whether sales recover and whether the company converts its improved gross margin into better operating profit.